Ajanta Pharma - A multibagger
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of specialty pharmaceutical quality finished dosages. It has business in India, U.S and other countries like Philippines, Middle East and Africa.
Business Strategy and margin revival:
- Three pillars: Smart product selection, superior formulation development capabilities, focused business segments.
- Will focus on branded generic business and allocate more resources on product registrations, team, and launch of new products which will increase marketing expenses.
- FY23 EBITDA margins were impacted from higher raw material prices, higher freight costs and US price erosion. Management expects it to climb back to about 25% in FY24.
Some details of the company-
Return on capital employed >30 AND
Debt to equity <0.1 AND
Net profit preceding 12months >500 AND
Net Profit latest quarter >100
I am not a SEBI registered analyst.
Please do your own analysis before investing.
Do like and follow and share among your friends and family.
Thank you.
Business Strategy and margin revival:
- Three pillars: Smart product selection, superior formulation development capabilities, focused business segments.
- Will focus on branded generic business and allocate more resources on product registrations, team, and launch of new products which will increase marketing expenses.
- FY23 EBITDA margins were impacted from higher raw material prices, higher freight costs and US price erosion. Management expects it to climb back to about 25% in FY24.
Some details of the company-
Return on capital employed >30 AND
Debt to equity <0.1 AND
Net profit preceding 12months >500 AND
Net Profit latest quarter >100
I am not a SEBI registered analyst.
Please do your own analysis before investing.
Do like and follow and share among your friends and family.
Thank you.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.